MX2025007322A - Tratamiento combinado de canceres que usa un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de punto de control inmune - Google Patents

Tratamiento combinado de canceres que usa un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de punto de control inmune

Info

Publication number
MX2025007322A
MX2025007322A MX2025007322A MX2025007322A MX2025007322A MX 2025007322 A MX2025007322 A MX 2025007322A MX 2025007322 A MX2025007322 A MX 2025007322A MX 2025007322 A MX2025007322 A MX 2025007322A MX 2025007322 A MX2025007322 A MX 2025007322A
Authority
MX
Mexico
Prior art keywords
cancer
cancers
antibody
immune checkpoint
checkpoint inhibitor
Prior art date
Application number
MX2025007322A
Other languages
English (en)
Spanish (es)
Inventor
Ernesto Isaac Wasserman
Eduardo Jose Pennella
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2025007322A publication Critical patent/MX2025007322A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2025007322A 2022-12-23 2025-06-20 Tratamiento combinado de canceres que usa un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de punto de control inmune MX2025007322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2033821 2022-12-23
PCT/NL2023/050684 WO2024136658A1 (en) 2022-12-23 2023-12-22 Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
MX2025007322A true MX2025007322A (es) 2025-07-01

Family

ID=85172568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025007322A MX2025007322A (es) 2022-12-23 2025-06-20 Tratamiento combinado de canceres que usa un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de punto de control inmune

Country Status (10)

Country Link
US (1) US20260217836A1 (cg-RX-API-DMAC10.html)
EP (1) EP4637817A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025542384A (cg-RX-API-DMAC10.html)
KR (1) KR20250124833A (cg-RX-API-DMAC10.html)
CN (2) CN120583961A (cg-RX-API-DMAC10.html)
AU (1) AU2023408531A1 (cg-RX-API-DMAC10.html)
IL (1) IL321614A (cg-RX-API-DMAC10.html)
MX (1) MX2025007322A (cg-RX-API-DMAC10.html)
TW (1) TW202432605A (cg-RX-API-DMAC10.html)
WO (1) WO2024136658A1 (cg-RX-API-DMAC10.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TWI717401B (zh) 2015-10-20 2021-02-01 南韓商東友精細化工有限公司 整合有偏光板之窗口基板、及製備該窗口基板之方法
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
IL303633A (en) * 2020-12-15 2023-08-01 Merus Nv Cancer treatment with an antibody that binds LGR5 and EGFR
CN120504741A (zh) * 2021-10-06 2025-08-19 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症

Also Published As

Publication number Publication date
EP4637817A1 (en) 2025-10-29
KR20250124833A (ko) 2025-08-20
TW202432605A (zh) 2024-08-16
CN122031678A (zh) 2026-05-15
AU2023408531A1 (en) 2025-07-17
US20260217836A1 (en) 2026-07-30
JP2025542384A (ja) 2025-12-25
WO2024136658A1 (en) 2024-06-27
CN120583961A (zh) 2025-09-02
IL321614A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
ZA201907225B (en) Treatment of her2 positive cancers
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX357100B (es) Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4.
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2024002711A (es) Anticuerpos de receptor de activina tipo-2a (anti-acvr2a) y usos de estos.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2022015375A (es) Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
EA202192757A1 (ru) Способ лечения опухолей
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
MX2025008524A (es) Métodos y composiciones para la terapia combinada
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
MX2023001233A (es) Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2.
MX2024013676A (es) Anticuerpos triespecificos para cumulo de diferenciacion 3 (cd3)/antigeno de maduracion de celulas b (bcma)/cumulo de diferenciacion (cd38)
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
MX2023012766A (es) Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores.
MX2023006983A (es) Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).